Home FOR AUTHORS Neoplasma 2021 Neoplasma Vol.68, No.6, p.1351–1358, 2021

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.68, No.6, p.1351–1358, 2021

Title: A novel intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of relapsed/refractory acute myeloid leukemia
Author: Yanling Sun, Jingwen Zhang, Bing Long, Xiangzhong Zhang, Ruijuan Wen, Yi He, Xudong Li

Abstract: We conducted a prospective study to evaluate the efficacy and safety of cladribine, cytarabine, mitoxantrone, and granulocyte colony-stimulating factor (CLAG-M) regimen combined with busulfan and cyclophosphamide (Bucy) as new intensive conditioning before allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of relapsed/refractory acute myeloid leukemia (AML). 24 patients were enrolled. The median follow-up was 15.2 months (range 1.9-67.0 months). Except for one patient who died before graft infusion, the evaluable 23 patients (96%) achieved complete remission (CR). The two-year overall survival (OS) rate and leukemia-free survival (LFS) rate were 61.4% and 59.4%, respectively. The non-relapse mortality (NRM) was 9.1%. Univariate analysis revealed that the myeloid blast phase of chronic myelomonocytic leukemia (CMML), an EVI1 mutated, blood blasts ≥ 20% at transplant and extramedullary disease were risk factors for LFS.

Keywords: relapsed/refractory acute myeloid leukemia; allogeneic hematopoietic stem cell transplantation; intensive conditioning regimen; CLAG-M
Published online: 11-Oct-2021
Year: 2021, Volume: 68, Issue: 6 Page From: 1351, Page To: 1358
doi:10.4149/neo_2021_210426N573


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.